Objective This collaboration between the American College of Rheumatology and the
American Association of Hip and Knee Surgeons developed an evidence‐based guideline …

Background and Objectives Five-tumour necrosis factor (TNF)-blockers (infliximab,
etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of …

Context Concerns exist regarding the potential development of malignancies in patients with
rheumatoid arthritis (RA) who are receiving biologic response modifiers (BRMs). Objective …

Background Interleukin-6 (IL-6) is a pro-inflammatory cytokine that has been found to be
increased in type 2 diabetic subjects. However, it still remains unclear if these elevated IL-6 …

Objective To evaluate the effect of different concomitant disease modifying antirheumatic
drugs (DMARDs) on the persistence with antitumour necrosis factor (anti-TNF) therapies in …

Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin
lymphoma (HL) and non‐HL than the general population. Non‐Hodgkin lymphoma is more …

Objective The study objective was to evaluate and update the safety data from randomized
controlled trials of tumor necrosis factor inhibitors in patients treated for rheumatoid arthritis …

Objective The study aims to compare the efficacy and safety of biosimilar etanercept (SB4) to
original etanercept (ETN) in a real-life national cohort of rheumatoid arthritis (RA). Methods …

The study of cytokine storm in COVID-19 has been having different edges in accordance
with the knowledge of the disease. Various cytokines have been the focus, especially to …

Anti-TNFα medications have led to vast improvements in the treatment of inflammatory
conditions, including rheumatoid arthritis and Crohn's disease. As these diseases often …